{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:10:01Z","timestamp":1747199401141,"version":"3.40.5"},"reference-count":22,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>\n              Exploring the potential of\n              <jats:italic>BOLA3-DT<\/jats:italic>\n              as a diagnostic biomarker in prostate cancer.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>\n              Expression of the lncRNA\n              <jats:italic>BOLA3-DT<\/jats:italic>\n              was analyzed between normal and tumor samples in the GDC TCGA PRAD (Genomic Data Commons: The Cancer Genome Atlas Prostate Adenocarcinoma Collection) dataset. Disease progression-related clinicopathological parameters such as serum PSA level (ng\/ml) and Gleason score were associated with the expression of\n              <jats:italic>BOLA3-DT<\/jats:italic>\n              using the same GDC TCGA PRAD dataset. To validate these findings, the expression of\n              <jats:italic>BOLA3-DT<\/jats:italic>\n              was checked in our sample set of 15 PCa (prostate cancer) and 15 BPH (benign hypertrophy of the prostate) patients.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>\n              In the GDC TCGA PRAD dataset, the expression of the lncRNA\n              <jats:italic>BOLA3-DT<\/jats:italic>\n              was significantly downregulated in prostate cancer tissue samples (\n              <jats:italic>n<\/jats:italic>\n              \u2009=\u2009492) compared to adjacent normal (\n              <jats:italic>n<\/jats:italic>\n              \u2009=\u200952;\n              <jats:italic>p<\/jats:italic>\n              \u2009&lt;\u20090.0001), and, there was a significant negative correlation between the expression of the lncRNA\n              <jats:italic>BOLA3-DT<\/jats:italic>\n              and the serum PSA level (\n              <jats:italic>p<\/jats:italic>\n              \u2009&lt;\u20090.01). However, no significant association was found between the lncRNA\n              <jats:italic>BOLA3-DT<\/jats:italic>\n              expression and the Gleason score (\n              <jats:italic>p<\/jats:italic>\n              \u2009&gt;\u20090.05). In this study, it was found that\n              <jats:italic>BOLA3-DT<\/jats:italic>\n              was downregulated in PCa tissue samples compared to BPH samples (\n              <jats:italic>p<\/jats:italic>\n              \u2009&gt;\u20090.05). In the GDC TCGA PRAD dataset, it was revealed that BOLA3-DT could serve as an excellent diagnostic marker with a sensitivity of 86.9% and a specificity of 84.6% (AUC-0.916).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>\n              LncRNA\n              <jats:italic>BOLA3-DT<\/jats:italic>\n              , a novel long non-coding RNA, was found to be downregulated in prostate cancer. The expression of the lncRNA\n              <jats:italic>BOLA3-DT<\/jats:italic>\n              can serve as a diagnostic marker in prostate cancer.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1177\/03915603251314995","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:51:48Z","timestamp":1737697908000},"page":"267-272","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the potential of\n            <i>BOLA3-DT<\/i>\n            as a diagnostic biomarker in prostate cancer"],"prefix":"10.1177","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8929-0961","authenticated-orcid":false,"given":"Debansu","family":"Sarkar","sequence":"first","affiliation":[{"name":"Department of Urology, IPGMER and SSKM Hospital, Kolkata, West Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badre Alam","family":"Khan","sequence":"additional","affiliation":[{"name":"IPGMER and SSKM Hospital, Kolkata, West Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2314-2525","authenticated-orcid":false,"given":"Abhishek","family":"Bardhan","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Presidency University, Kolkata, West Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amlan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Presidency University, Kolkata, West Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilip Kumar","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Urology, IPGMER and SSKM Hospital, Kolkata, West Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31827da979"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/765207"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30546"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2009.07.004"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.12954\/PI.12011"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.02.006"},{"issue":"23","key":"e_1_3_3_9_2","first-page":"5975","article-title":"DD3: a new prostate-specific gene, highly overexpressed in prostate cancer","volume":"59","author":"Bussemakers MJ","year":"1999","unstructured":"Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59(23): 5975\u20135979.","journal-title":"Cancer Res"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64024-4"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2005.10.002"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.09088.x"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39498.525706.AD"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2017.03.06"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27284"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80620-0"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3606"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108652"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02230-y"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.07.023"},{"issue":"6","key":"e_1_3_3_21_2","first-page":"459","article-title":"The role of urine prostate cancer antigen 3 mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients","volume":"18","author":"Ng CF","year":"2012","unstructured":"Ng CF, Yeung R, Chiu PK, et al. The role of urine prostate cancer antigen 3 mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients. Hong Kong Med J 2012; 18(6): 459\u2013465.","journal-title":"Hong Kong Med J"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11683.x"},{"key":"e_1_3_3_23_2","first-page":"553","article-title":"Predicting prostate biopsy outcome using a PCA3-based nomogram in a polish cohort","volume":"33","author":"Salagierski M","year":"2013","unstructured":"Salagierski M, Mulders P, Schalken JA. Predicting prostate biopsy outcome using a PCA3-based nomogram in a polish cohort. Anticancer Res 2013; 33: 553\u2013558.","journal-title":"Anticancer Res"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603251314995","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603251314995","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603251314995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:41:41Z","timestamp":1747197701000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603251314995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/03915603251314995"],"URL":"https:\/\/doi.org\/10.1177\/03915603251314995","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"type":"print","value":"0391-5603"},{"type":"electronic","value":"1724-6075"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}